Fatigue a Long COVID-19 Symptom Substudy of FSC19-KN Trial
NCT ID: NCT04883190
Last Updated: 2024-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
353 participants
OBSERVATIONAL
2021-05-15
2024-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Follow-up Study of COVID-19 Patients in the District Konstanz
NCT04724434
Evaluation of Inflammatory Cytokines During COVID-19
NCT04824495
The Natural History of Hospitalized COVID-19 Patients
NCT04424992
Post-coronavirus Disease-2019 Fatigue
NCT04851561
Impact of Severe Acute Respiratory Syndrome (SARS-CoV-2/COVID-19) Related Pneumonia on Lung Function and Structure.
NCT04916834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
And the occurrence of Major Depressive Disorder, other depressive Syndrome or Panic syndrome measured by Brief Patient Health Questionnaire.
The FSC19-KN trial already included patients with positive test for SARS-CoV-2 by PCR and volunteers with negative SARS-CoV-2 antibody testing. Verification of exclusion criteria had been completed in the main trial FSC19-KN. After the informed consent to participation in the sub-study is given all inclusion modalities are fulfilled.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. after SARS-CoV-2 infection
All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.
We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group.
Fulfilling Questionaires
Fulfilling Questionaires PHQ-D (brief) and FSMC
2. control group with negative antibody test
All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.
We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group.
Fulfilling Questionaires
Fulfilling Questionaires PHQ-D (brief) and FSMC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fulfilling Questionaires
Fulfilling Questionaires PHQ-D (brief) and FSMC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participation in the FSC19-KN study
2. Consent to participate in the survey
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hegau-Bodensee-Klinikum Singen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Kollum, PD Dr.
Role: PRINCIPAL_INVESTIGATOR
Hegau-Bodensee-Klinikum Singen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hegau Bodensee Klinikum Singen
Singen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sabrina Geng, Jonas Haberland, Elisabeth Haberland, Julia Hromek, Heidi Zimmermann, et al, (2024), Effects on Fatigue and Depression 11 And 19 Months after a Sars-Cov-2 Infection a Case Control Study, J. Clinical Cardiology and Cardiovascular Interventions, 7(2); DOI:10.31579/2641-0419/348
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-1340
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.